Cadmus Rich - 28 Oct 2021 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Medical Officer Head of R&D
Signature
/s/ Julie Feder
Issuer symbol
AURA
Transactions as of
28 Oct 2021
Net transactions value
$0
Form type
3
Filing time
28 Oct 2021, 20:30:20 UTC
Next filing
02 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AURA Stock Option (Right to Buy) 28 Oct 2021 Common Stock 29,197 $5.21 Direct F1
holding AURA Stock Option (Right to Buy) 28 Oct 2021 Common Stock 80,291 $2.74 Direct F2
holding AURA Stock Option (Right to Buy) 28 Oct 2021 Common Stock 18,248 $3.15 Direct F3
holding AURA Stock Option (Right to Buy) 28 Oct 2021 Common Stock 41,422 $4.25 Direct F4
holding AURA Stock Option (Right to Buy) 28 Oct 2021 Common Stock 125,547 $5.48 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option are fully vested as of October 23, 2021.
F2 The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of February 21, 2018 with the remainder vesting thereafter pro-rata in 36 monthly installments.
F3 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2019
F4 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2020
F5 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021

Remarks:

Chief Medical Officer Head of R&D